Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11576864 Sustained-release dosage forms of ruxolitinib

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

February 14, 2023

Patent Application Number

17847734

Date Filed

June 23, 2022

Patent Citations

US Patent 10513522 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors

US Patent 10561616 Sustained release dosage forms for a JAK1 inhibitor

US Patent 10639310 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors

US Patent 10640506 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors

US Patent 10695337 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors

US Patent 10766900 Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof

US Patent 10874616 Sustained-release dosage forms of ruxolitinib

US Patent 11045421 Sustained release dosage forms for a JAK1 inhibitor

...

Patent Primary Examiner

Umamaheswari Ramachandran

CPC Code

The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11576864 Sustained-release dosage forms of ruxolitinib

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.